Nvidia stock rises Wednesday. But the chip maker faces an increasing number of rivals in the U.S. and China. ...

Bostic says Fed should pause rate cuts, Warner Bros. to tell shareholders to reject Paramount bid, Medline set to trade in IPO, and more news to start your day. ...

Sign in to access your portfolio Sign in ...

Core Insights - The U.S. automotive industry is experiencing a shift away from fully electric vehicles (EVs), as evidenced by Ford's recent announcement to scale back its EV-focused business strategy, including scrapping plans for a new electric truck and converting its F-150 Lightning to a hybrid model [1][2][9] Industry Challenges - Manufacturing costs for vehicles in the U.S. have risen due to higher labor costs, stricter environmental regulations, and supply chain issues, leading to increased investment risk [4][5] - Regulatory changes and the elimination of federal tax credits for EVs have added uncertainty to investment decisions in U.S. manufacturing [5][6] - Ford's flagship EV, the F-150 Lightning, has faced profitability issues, with the cost of production rising significantly from an initial price of $40,000 to around $55,000 for the 2025 model [6][7] Market Dynamics - Despite record-high EV sales in the U.S. this year, the market is still heavily influenced by consumer sentiment, which has shown signs of decline, particularly among gas and hybrid vehicle drivers [15][16] - The global EV market is dominated by China, which accounts for approximately 70% of global EV production, highlighting the competitive challenges faced by U.S. automakers [11][12] Future Outlook - While Ford is scaling back on larger electric vehicles, it plans to focus on smaller, more affordable models and expand its hybrid offerings [10][19] - Experts remain optimistic about the long-term potential of EVs, citing advancements in battery technology and the overall positive experience of EV ownership [18][19] - The U.S. EV industry has faced fluctuations before, and while current economic conditions may justify a pullback, there is a risk of falling behind when the market rebounds [20]

Core Insights - Protalix BioTherapeutics and Secarna Pharmaceuticals have entered into a collaboration and option agreement to develop antisense oligonucleotide therapies for rare renal diseases, leveraging Protalix's expertise in rare diseases and Secarna's AI-powered OligoCreator platform [1][2][3] Company Overview - Protalix BioTherapeutics focuses on innovative therapeutics for rare diseases and has developed two enzyme replacement therapies available in multiple markets, utilizing a proprietary plant cell-based expression system called ProCellEx [4][5] - Secarna Pharmaceuticals specializes in oligonucleotide therapeutics and employs its OligoCreator platform to rapidly generate high-quality antisense candidates, aiming to transform untreatable conditions into treatable ones [7] Collaboration Details - The collaboration involves Protalix selecting pharmaceutical targets for rare renal indications, while Secarna will use its OligoCreator platform to design and profile ASO candidates against these targets [2] - Protalix has the option for an exclusive, worldwide license to further develop and commercialize the therapeutic programs resulting from this collaboration [2][3] Strategic Goals - The partnership aims to advance programs from preclinical stages to clinical trials, addressing significant unmet medical needs in the rare kidney disease space [2][3] - Both companies express excitement about the collaboration, highlighting the combination of Secarna's rapid candidate generation and Protalix's experience in bringing therapies to market [3]

Core Viewpoint - Sealed Air Corporation has entered into a definitive agreement with CD&R for an acquisition valued at $10.3 billion, with a purchase price of $42.15 per share, and the transaction is expected to close in mid-2026 [1][4]. Group 1: Transaction Details - The "go-shop" period for Sealed Air's acquisition expired on December 16, 2025, during which the company solicited alternative acquisition proposals from 29 parties, resulting in six parties entering confidentiality agreements [2]. - Following the expiration of the "go-shop" period, Sealed Air is now subject to "no-shop" provisions, limiting its ability to negotiate with third parties [3]. - The transaction is contingent upon stockholder approval, regulatory clearances, and other customary closing conditions [4]. Group 2: Company Overview - Sealed Air Corporation is a global leader in packaging solutions, generating $5.4 billion in sales in 2024 and employing approximately 16,400 people across 117 countries [6]. - The company specializes in food and protective packaging solutions, with well-known brands including CRYOVAC®, SEALED AIR®, LIQUIBOX®, AUTOBAG®, and BUBBLE WRAP® [6].

Core Insights - Positioning investment portfolios for 2026 is crucial, with a focus on selling stocks that have reached their full potential to lock in gains and free up cash [1] Group 1: Palantir - Palantir's AI-powered data analytics software has seen significant demand, resulting in a 63% year-over-year revenue increase in Q3 and a profit margin of 40% [4] - Despite strong business fundamentals, Palantir's stock is trading at an excessive valuation of 259 times forward earnings and 123 times sales, which is significantly higher than comparable companies like Nvidia [5] - Analysts predict a slowdown in revenue growth for Palantir, with expectations of 41% growth in 2026, down from 54% in 2025, indicating potential risks for the stock price [6] Group 2: BigBear.ai - BigBear.ai, a smaller AI stock, is facing a more severe issue as its revenue is shrinking, despite the overall demand for AI software [7] - The company focuses on providing custom AI solutions to the U.S. government and related sectors, but its lack of growth raises concerns about its future performance [8]

Core Insights - The U.S. Department of Health and Human Services (HHS) has added Duchenne muscular dystrophy (DMD) to the recommended newborn screening panel, which is seen as a significant advancement in early diagnosis and potential treatment opportunities in the biotech sector [1] Group 1: Industry Impact - The addition of DMD to the newborn screening panel is expected to create new market opportunities for biotechnology companies focused on developing therapies for this condition [1] - This decision may lead to increased investment and research in the field of genetic disorders, particularly in the development of innovative treatments for DMD [1] Group 2: Analyst Perspective - The analyst emphasizes the importance of combining scientific expertise with financial analysis to identify promising biotechnology companies that are innovating in unique ways [1] - The focus is on evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities, while also considering financial fundamentals and valuation [1]

Key Information - Rathbones Group Plc disclosed a position in The Unite Group Plc, holding 602,285 relevant securities, representing 0.12% of the total [1][3] - The disclosure date for the position held was December 16, 2025 [1] - The disclosure includes interests in relevant securities and short positions, with no short positions reported [3] Positions - The total interests in the relevant securities of The Unite Group Plc are 602,285 shares, which is 0.12% of the total [3] Dealings - Rathbones Group Plc sold 140 ordinary shares at a price of 533.73 pence per unit [7]

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV- 304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial showed KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically signific. ...